To develop these novel products, investor capital is often needed to support these therapies from preclinical development through clinical trials, and ultimately, to commercialization.
- Venture Capital Groups
- Private Equity Firms
- Hedge Funds
- Investment Firms
- Endowment Funds
- Family Offices
- Angel Investors
This database reveals the
identity and investment behavior of 300+ investors who specialize in companies commercializing regenerative medicine (RM) and advanced therapy (AT) products.
It is designed to be used by companies who are pursuing or considering a capital raise, including:- Seed rounds
- Venture rounds
- Private placements
- Loans and convertible debt
- Any expansion or company growth requiring outside funding
It takes our analysts hundreds of hours of research to uncover these RM investors from across the globe. Importantly, we utilize translators and crowd-source feedback from BioInformant’s partners, clients, colleagues, and global readership.
Thus, this database includes little known investors that would be difficult to identify if you had not been tracking this industry daily for the past 19+ years (as BioInformant has done).
If you are in the process of raising investor capital for your company, product candidate, or clinical trial, then this database is a must-have.
For 48 hours only, you can claim it for an unusual $150 off:
Remember to act fast, because the offer expires soon.
Be Great,
The BioInformant Team
p.s. Interested in other market areas, such as iPSCs, CAR-T, Exosomes, Cord Blood & Tissue, Regenerative Medicine, and beyond?
p.p.s. Have news to share with BioInformant's large global readership? Reply to this email to get in touch.
